Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Placebo-controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib at 6 mg/kg/Day to Placebo in Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap

NCT00814073 is registered in ClinicalTrials.gov with AB Science as lead sponsor.

NCT NCT00814073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00814073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Placebo-controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib at 6 mg/kg/Day to Placebo in Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap
Lead sponsor
AB Science
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2008
Completion date
November 30, 2015
Enrollment
135 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

indolent systemic mastocytosis